Brian Schwartz, MD
Endocrinology, Diabetes & Metabolism · New York, NYNPI 1629131958
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $319 of the $378 with a category attached, or 84.3%. 8 manufacturers reported payments, led by Boston Scientific at 39.0% of the total. Reporting peaked in 2023 at $167 and has fallen 51.0% since, to $82 in 2025. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in NY, where the typical reported total is $1,058.
Across 10 payments — averaging $37.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$148
- Mannkind Corporation$59
- Pfizer$43
- Abbott$29
- Braemar Manufacturing, LLC$27
- Bayer$26
- plus $46 from 2 others
What the payments were for
- Food & beverage$31984%
- Gifts$5916%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 1 | $148 |
| Mannkind Corporation | 1 | $59 |
| Pfizer | 3 | $43 |
| Abbott | 1 | $29 |
| Braemar Manufacturing, LLC | 1 | $27 |
| Bayer | 1 | $26 |
| Foundation Fusion Solutions, LLC | 1 | $26 |
| Amgen | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$378 in reported general payments places this provider in the 35th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
See all endocrinology, diabetes & metabolism providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 235 | $396,709 |
| JardianceEmpagliflozin | 288 | $375,261 |
| MounjaroTirzepatide | 107 | $184,218 |
| JanuviaSitagliptin Phosphate | 62 | $81,436 |
| TrulicityDulaglutide | 14 | $27,311 |
| FarxigaDapagliflozin Propanediol | 20 | $24,241 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 37 | $22,607 |
| Tresiba Flextouch U-100Insulin Degludec | 35 | $18,529 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 19 | $14,910 |
| RybelsusSemaglutide | 13 | $14,442 |
| Tresiba Flextouch U-200Insulin Degludec | 13 | $13,966 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $12,217 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 20 | $9,679 |
| Gvoke Hypopen 2-PackGlucagon | 15 | $9,493 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 71 | $7,495 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in New York
- John BilezikianNew York$809K
- Anastasios ManessisNew York$656K
- Jason BakerNew York$427K
- Brian LevyNew York$417K
- Stuart WeissNew York$275K
- Priya JaisinghaniNew York$239K
- Henry GinsbergNew York$161K
- Recaredo BerbanoNew York$146K
- Beverly TchangNew York$120K
- Shira EytanNew York$96K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.